NOSH-aspirin (NBS-1120) inhibits estrogen receptor–negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways
The Journal of Pharmacology and Experimental Therapeutics · 2025
DOI: 10.1124/jpet.124.002240 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025. Verfasst von Mitali Chattopadhyay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medici…. Hauptthemen laut MEDLINE: Aspirin, Signal Transduction, Receptors, Estrogen, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, NIH, National Cancer Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York.
- Department of Biological and Chemical Sciences, New York Institute of Technology, New York, New York.
- Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York; Graduate Program in Biology, City University o…
Förderung
- NIMHD NIH HHS
- NIH
- National Cancer Institute
Zitieren
APA
Chattopadhyay, M., Nath, N., Kodela, R., Metkar, S., Soyemi, S. A., & Kashfi, K. (2025). NOSH-aspirin (NBS-1120) inhibits estrogen receptor–negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.124.002240
Vancouver
Chattopadhyay M, Nath N, Kodela R, Metkar S, Soyemi SA, Kashfi K. NOSH-aspirin (NBS-1120) inhibits estrogen receptor–negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways. The Journal of Pharmacology and Experimental Therapeutics. 2025. doi:10.1124/jpet.124.002240
BibTeX
@article{Chattopadhyay2025,
author = {Chattopadhyay, Mitali and Nath, Niharika and Kodela, Ravinder and Metkar, Shalaka and Soyemi, Sarin A and Kashfi, Khosrow},
title = {NOSH-aspirin (NBS-1120) inhibits estrogen receptor–negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2025},
doi = {10.1124/jpet.124.002240}
}
EUVIMED